Antiphospholipid antibodies differ in aPL cofactor requirement. Academic Article uri icon

Overview

abstract

  • Although autoimmune antiphospholipid antibodies (aPL) may require a serum cofactor, beta 2-glycoprotein I (beta 2GPI), for maximal binding in aPL ELISA, it is not known whether cofactor is absolutely required or is merely an enhancing factor for binding, nor is it clear whether aPL bind to cofactor itself, a cofactor-lipid complex, or a phospholipid modified in some way by cofactor. We therefore isolated and purified beta 2GPI and evaluated its relationship to both IgG and IgM aPL binding. aPL derived from different sera appear to have differing requirements for cofactor; the proportion of total binding attributable to cofactor varies from 46% to 95%. aPL do not bind to beta 2GPI in the absence of phospholipid. Enhanced binding to phospholipid is seen if beta 2GPI is provided either before or with the test antibody. Autoimmune aPL bind phospholipid better with human rather than bovine cofactor. The requirement for cofactor is greater for low-avidity aPL as measured in an IgG-human cofactor system. Cofactor requirement alone does not predict the presence or absence of associated clinical complications.

publication date

  • February 1, 1992

Research

keywords

  • Antibodies, Antiphospholipid
  • Glycoproteins

Identity

Scopus Document Identifier

  • 0026817097

Digital Object Identifier (DOI)

  • 10.1177/096120339200100205

PubMed ID

  • 1301968

Additional Document Info

volume

  • 1

issue

  • 2